Search for a trial

Grey matter microglial imaging with [18F]DPA-714 in progressive MS patients

The main objective of this study is to depict microglial activation behind a closed BBB in vivo and possibly establish an imaging marker of fast clinical progression, we will aim at visualizing microglial activity in vivo in cortical and hippocampal…

An Open label Follow-On Study to Assess the Ongoing Safety of MBP8298 in Subjects with Secondary Progressive Multiple Sclerosis.

To obtain ongoing safety data of 500 mg MBP8298 given intravenously every six months in subjects previously enrolled in the MBP8298-01 study *A Double Blind Placebo Controlled Multi-Centre Study to Evaluate the Efficacy and Safety of MBP8298 in…

A Phase 2b dose-finding study for SAR442168, a Bruton's tyrosine kinase inhibitor, in participants with relapsing multiple sclerosis

Primary: - To determine the dose-response relationship for SAR442168 to reduce the number of new active brain lesions. Secondary: - To evaluate efficacy of SAR442168 on disease activity, assessed by clinical and imaging measures.- To evaluate the…

A Phase 1/2 Open-Label, Multicenter, Dose Ranging and Confirmatory Study to Assess the Safety, Tolerability and Efficacy of PBKR03 Administered to Pediatric Subjects with Early Infantile Krabbe Disease (Globoid Cell Leukodystrophy) (GALax-C)

This first-in-human study is planned to include both a dose ranging phase and a confirmatory phase, with the intention that all data collected throughout the study may support registration. The dose ranging phase will be conducted in cohorts of 3-4…

An Open-Label Extension Study to Investigate the Long-Term Safety, Tolerability, and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

CIDP04 is a Phase 2A, multicenter, single-arm, open-label study with the primary objective of evaluating the long-term safety and tolerability of rozanolixizumab when administered as weekly subcutaneous (sc) infusion in subjects with CIDP. The…

[11C]MeDAS PET: an imaging tool for quantitative assessment of changes in myelin density over time in multiple sclerosis

The objective of this study is to evaluate [11C]MeDAS PET as a quantitative method for assessment of changes in myelin density over time and thus the efficacy of [11C]MeDAS PET to image myelin degradation and repair.

Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

This study has been transitioned to CTIS with ID 2023-507885-21-00 check the CTIS register for the current data. Primary objective:- To assess the long-term safety and tolerability of efgartigimod PH20 SC (efgartigimod co formulated with recombinant…

A Phase 2, multicenter, open-label, non-randomized, proof-of-concept study evaluating the efficacy, safety, and tolerability of SAR445088 (previously BIVV020) in adults with chronic inflammatory demyelinating polyneuropathy (CIDP)

This study has been transitioned to CTIS with ID 2024-512345-16-00 check the CTIS register for the current data. The purpose of this BIVV020 Phase 2 study is to determine the preliminary efficacy, safety, and tolerability of BIVV020 in three CIDP…

Long-term extension safety and efficacy study of SAR442168 in participants with relapsing multiple sclerosis.

Primary: to determine the long-term safety and tolerability of SAR442168 in RMS participants. Secondary: to evaluate efficacy of SAR442168 on disease activity, assessed by clinical and imaging methods.

Multicenter, randomized, double-blind, parallel-group extension to study AC 058B201 to investigate the long-term safety, tolerability, and efficacy of 10, 20, and 40 mg/day ponesimod, an oral S1P1 receptor agonist, in patients with relapsing-remitting multiple sclerosis

* To investigate the long-term safety and tolerability of ponesimod * To investigate the long-term efficacy of ponesimod* To explore the dose response relationship of 10, 20 and 40 mg ponesimod on lymphocyte count, MRI endpoints and annualized…

Neuroprotective Effects of Exercise in People with Progressive Multiple Sclerosis: a phase II trial

The primary aim of this phase II trial is to assess whether a progressive resistance training program can slow down neurodegeneration in people with PMS. Additional objectives of this study are: 1. To determine the effect of exercise on disability.…